Lancet

We thank Alexander Sherry and colleagues and Sheng Zhang and colleagues for their interest in the First International Randomized study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP) phase 2 trial methodology.

Naci H, Murphy P, Woods B, Lomas J, Wei J, Papanicolas I. Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis. Lancet 2025; 405: 50–60—The copyright line now indicates that this Article has an Open Access licence. This correction has been made to the online version as of Jan 30, 2025.

The Lancet. Infectious diseases in 2025: a year for courage and conviction. Lancet 2025; 405: 97—The International Day of Epidemic Preparedness was on Dec 27. This change has been made to the online version as of Jan 30, 2025.

For patients aged 50 years or older and at 3 years post diagnosis, less frequent mammograms were non-inferior compared with annual mammograms for breast cancer-specific survival, recurrence-free interval, and overall survival, and should be considered for this population.

The incidence and geographical distribution of suspected mpox cases have increased substantially since 2010. Improvements in surveillance and decentralised testing are essential to monitor mpox trends and direct interventions effectively, to address the public health emergency declarations issued in August, 2024.